NCT02225548

Sagene 2014 - Parkinson's Disease and Erectile Dysfunction

An Open-label Trial of Oral Selegiline 5 or 10 mg and Tadalafil 2.5mg Co-administration to Male Patients With Parkinson's Disease and Moderate Erectile Dysfunction.

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: University of South Florida · Academic / Other
• Sex: Male
• Age: 40 Years – 64 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to see if selegiline and tadalafil (generic for Cialis®) results in an improvement in Erectile dysfunction (ED) in male patients with Parkinson's disease (PD) and moderate ED. Male PD patients who have an incomplete response to tadalafil alone will be given both medications to see if the addition of selegiline improves ED symptoms more than tadalafil alone. It is common practice for a medical doctor to prescribe these two drugs to a patient like you. However, there have been no studies conducted to examine the effects of these medications when taken together. Selegiline is normally prescribed for PD patients that are taking carbidopa/levodopa who are not receiving complete benefit from carbidopa/levodopa. Tadalafil is normally prescribed to men who have erectile dysfunction and/or benign prostatic hyperplasia (BPH).

Conditions

• Parkinson's Disease
• Erectile Dysfunction

Interventions

Type	Name	Description
DRUG	Selegiline
DRUG	Tadalafil

Timeline

• Start date: 2014-09-01
• Primary completion: 2018-12-01
• Completion: 2019-01-01
• First posted: 2014-08-26
• Last updated: 2017-12-20

Locations

1 site across 1 country: United States